Use of ICS/LABA on asthma exacerbation risk in patients within a medical group
BACKGROUND: Asthma medication ratio (AMR) >= 0.5 has been shown to predict asthma exacerbations. This study explores the impact of increasing or decreasing inhaled corticosteroid/long-acting beta-agonist (ICS/LABA) use over a 7-year period on achieving an AMR of >= 0.5. OBJECTIVES: To (a) assess the impact of increasing use of ICS/LABAs on changes in a modified AMR (mAMR) and (b) examine asthma risk over time as measured by an mAMR over a 7-year period, adjusting for differences in baseline characteristics. METHODS: This is a retrospective, observational study using pharmacy and medical claims from a medical group from January 1, 2003, to December 31, 2010. All patients with a 1 asthma diagnosis (ICD-9-CM, 493.xx) with >= 1 inhaled asthma medication dispensed in each year of eligibility were included. The mAMR=total ICS controllers dispensed/(total ICS controllers dispensed + albuterol dispensed). The proportion of ICS/LABA use was determined as the number of ICS/LABA canisters dispensed/(total of ICS/LABA+ICS dispensed). Generalized linear mixed models were used to assess the effect of incremental change in ICS/LABA use on mAMR over 7 years, adjusting for differences in resource utilization, time, and asthma medication use. RESULTS: Nine hundred ninety patients (mean age [+/-SD] 34.7 years [+/- 18.2], 61.7% female) met all criteria. Overall, mean mAMR increased over time, while mean albuterol use decreased over time. Adjusting for covariates, we found that a 10% increase in ICS/LABA use was associated with a 9% increase (adjusted OR = 1.09, 95% CI = 1.06-1.12) in the likelihood of achieving an mAMR >= 0.5, while a 50% increase in ICS/LABA use was associated with a 53% increase (OR = 1.53, 95% CI = 1.31-1.80) in the likelihood of achieving an mAMR >= 0.5. CONCLUSIONS: Increase in ICS/LABA use over time in a population of asthma patients was significantly associated with a higher likelihood of achieving an mAMR >= 0.5. Copyright (C) 2015, Academy of Managed Care Pharmacy. All rights reserved.
Stanford, RH., Nagar, S., Lin, XW., & O'Connor, RD. (2015). Use of ICS/LABA on asthma exacerbation risk in patients within a medical group. Journal of managed care & specialty pharmacy, 21(11), 1014-1019. https://doi.org/10.18553/jmcp.2015.21.11.1014